Stock listing
Lang & Schwarz:A1JJA3 Insmed Incorporated Aktie
German listing (Lang & Schwarz) of Insmed Incorporated · home listing NASDAQ:INSM
Follow Insmed Incorporated into a list and get an email when it puts out news.
Home listing price · NASDAQ:INSM
$141.33 USD +21.53 (+18.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:INSM
- Day range
- $140.99 – $150.00 USDNov 20, 2026
- Volume
- 6.22M sharesNov 20, 2026
- Market cap
- $31.01B USDAt the close on Nov 20, 2026 · price × 219.4M shares outstanding
- 52-week range
- $90.39 – $212.75 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $320.9M USDMedian day 2.47M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:INSM · Home | $141.33 USD | +21.53 (+18.0%) | 6,215,617 | $143.98 | $150.00 | $140.99 | $119.80 | Close on Nov 20, 2026 |
| LSE:0JAV | $143.51 USD | -0.29 (-0.2%) | 2,379 | $144.60 | $150.00 | $140.00 | $143.80 | Close on Nov 20, 2026 |
| Frankfurt:IM8N | €124.86 EUR | +14.02 (+12.6%) | — | €109.80 | €124.86 | €109.80 | €110.84 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:INSM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $141.33 | +21.53 | +18.0% | $143.98 | $150.00 | $140.99 | 6,215,617 | |
| $119.80 | -2.06 | -1.7% | $121.86 | $122.42 | $118.83 | 1,943,909 | |
| $121.86 | -1.02 | -0.8% | $122.30 | $123.30 | $118.54 | 2,397,604 | |
| $122.88 | +1.72 | +1.4% | $121.63 | $124.90 | $121.00 | 2,232,470 | |
| $121.16 | +3.09 | +2.6% | $118.18 | $121.50 | $116.97 | 1,543,586 | |
| $118.07 | -2.68 | -2.2% | $119.00 | $119.74 | $116.89 | 2,397,426 | |
| $120.75 | +1.26 | +1.1% | $119.49 | $120.88 | $117.36 | 1,488,398 | |
| $119.49 | +3.39 | +2.9% | $114.46 | $119.84 | $113.81 | 3,346,693 | |
| $116.10 | +1.695 | +1.5% | $114.82 | $116.36 | $112.61 | 2,668,731 | |
| $114.41 | +5.645 | +5.2% | $108.57 | $114.65 | $107.29 | 3,378,881 | |
| $108.76 | -1.24 | -1.1% | $109.40 | $109.98 | $106.18 | 2,616,032 | |
| $110.00 | +5.56 | +5.3% | $106.85 | $110.81 | $102.82 | 4,944,157 | |
| $104.44 | -4.87 | -4.5% | $109.31 | $111.11 | $104.30 | 6,215,992 | |
| $109.31 | -3.27 | -2.9% | $112.68 | $113.05 | $109.22 | 4,239,414 | |
| $112.58 | +0.99 | +0.9% | $113.60 | $116.37 | $111.97 | 5,184,139 | |
| $111.59 | +14.61 | +15.1% | $108.17 | $114.51 | $103.78 | 11,217,794 | |
| $96.98 | +2.02 | +2.1% | $94.01 | $97.92 | $93.91 | 4,646,019 | |
| $94.96 | +1.63 | +1.7% | $93.33 | $96.34 | $92.87 | 3,348,161 | |
| $93.33 | -0.06 | -0.1% | $94.02 | $94.34 | $92.96 | 3,379,731 | |
| $93.39 | -1.67 | -1.8% | $94.12 | $94.64 | $92.63 | 3,410,530 | |
| $95.06 | +1.02 | +1.1% | $93.50 | $95.59 | $93.33 | 3,099,798 | |
| $94.04 | -1.63 | -1.7% | $95.08 | $97.09 | $93.80 | 2,970,356 | |
| $95.67 | +0.38 | +0.4% | $95.44 | $97.20 | $94.60 | 2,612,666 | |
| $95.29 | -0.98 | -1.0% | $96.27 | $97.88 | $94.38 | 2,723,597 | |
| $96.27 | -2.94 | -3.0% | $98.70 | $99.00 | $96.05 | 2,396,400 | |
| $99.21 | +1.42 | +1.5% | $99.26 | $100.72 | $97.90 | 3,346,600 | |
| $97.79 | +1.00 | +1.0% | $97.39 | $98.00 | $95.76 | 2,736,400 | |
| $96.79 | -1.77 | -1.8% | $98.18 | $99.73 | $96.54 | 2,161,100 | |
| $98.56 | -2.04 | -2.0% | $98.82 | $100.31 | $98.33 | 1,696,000 | |
| $100.60 | +0.12 | +0.1% | $100.52 | $101.82 | $99.15 | 2,474,300 | |
| $100.48 | -1.26 | -1.2% | $100.66 | $101.06 | $96.68 | 5,251,800 | |
| $101.74 | -3.49 | -3.3% | $103.87 | $104.80 | $101.60 | 3,164,000 | |
| $105.23 | +1.40 | +1.3% | $103.97 | $107.87 | $101.32 | 3,685,700 | |
| $103.83 | -7.29 | -6.6% | $105.50 | $108.75 | $101.65 | 5,394,700 | |
| $111.12 | +2.53 | +2.3% | $107.76 | $111.54 | $105.68 | 4,136,200 | |
| $108.59 | -5.55 | -4.9% | $114.68 | $116.19 | $108.48 | 2,646,300 | |
| $114.14 | -1.49 | -1.3% | $115.65 | $116.43 | $113.60 | 2,868,400 | |
| $115.63 | -2.04 | -1.7% | $117.06 | $118.50 | $114.49 | 1,668,200 | |
| $117.67 | -0.16 | -0.1% | $116.83 | $119.32 | $116.31 | 1,744,400 | |
| $117.83 | -3.72 | -3.1% | $121.87 | $122.90 | $115.87 | 2,672,700 | |
| $121.55 | +3.21 | +2.7% | $119.26 | $121.69 | $118.38 | 2,233,600 | |
| $118.34 | -2.48 | -2.1% | $121.58 | $122.65 | $116.74 | 1,921,600 | |
| $120.82 | -0.18 | -0.1% | $121.00 | $122.48 | $119.09 | 2,405,300 | |
| $121.00 | +1.00 | +0.8% | $123.06 | $124.48 | $120.92 | 1,811,900 | |
| $120.00 | -3.98 | -3.2% | $123.89 | $124.11 | $119.32 | 3,443,200 | |
| $123.98 | +1.40 | +1.1% | $124.16 | $127.40 | $122.88 | 1,591,800 | |
| $122.58 | +2.66 | +2.2% | $120.00 | $124.41 | $119.55 | 1,433,800 | |
| $119.92 | -5.38 | -4.3% | $126.10 | $126.10 | $118.34 | 3,364,300 | |
| $125.30 | -4.11 | -3.2% | $129.50 | $130.78 | $124.58 | 1,610,500 | |
| $129.41 | +2.13 | +1.7% | $127.98 | $130.25 | $126.52 | 1,698,200 | |
| $127.28 | -1.52 | -1.2% | $127.22 | $128.85 | $124.29 | 2,594,500 | |
| $128.80 | +3.91 | +3.1% | $124.00 | $130.83 | $121.04 | 2,841,800 | |
| $124.89 | -1.40 | -1.1% | $124.78 | $127.42 | $121.38 | 1,604,100 | |
| $126.29 | -0.39 | -0.3% | $126.00 | $128.24 | $125.62 | 1,802,700 | |
| $126.68 | +0.05 | 0.0% | $126.70 | $127.09 | $124.05 | 1,885,200 | |
| $126.63 | +5.12 | +4.2% | $121.11 | $126.79 | $121.11 | 1,998,200 | |
| $121.51 | -0.31 | -0.3% | $121.95 | $122.19 | $119.52 | 1,419,300 | |
| $121.82 | +3.28 | +2.8% | $118.68 | $122.71 | $117.51 | 2,389,700 | |
| $118.54 | -2.85 | -2.3% | $120.11 | $120.66 | $117.15 | 1,977,500 | |
| $121.39 | -3.00 | -2.4% | $124.67 | $126.10 | $121.21 | 1,056,100 | |
| $124.39 | +0.50 | +0.4% | $122.89 | $125.59 | $121.64 | 1,979,900 | |
| $123.89 | -0.09 | -0.1% | $124.65 | $127.18 | $122.87 | 2,373,100 | |
| $123.98 | -1.79 | -1.4% | $125.03 | $126.11 | $122.83 | 1,340,900 | |
| $125.77 | +0.69 | +0.6% | $125.22 | $127.20 | $124.82 | 1,124,500 | |
| $125.08 | -5.58 | -4.3% | $128.36 | $130.27 | $124.60 | 1,761,700 |
Splits
2 splits since 2000 · NASDAQ:INSM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-4 | Consolidation |
- Ticker
- Lang & Schwarz:A1JJA3
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Insmed to Present at November and December 2026 Investor Conferences
Latest earnings call · Oct 29, 2026
Insmed (NASDAQ:INSM) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 29, 2026
Q3 2026 Earnings Presentation
Earnings · 27 slides
Latest news
Insmed to Present at November and December 2026 Investor Conferences
Nov 4, 2026
Closed $110.00 (+5.3%) on Nov 4, 2026
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
Oct 29, 2026
Closed $111.59 (+15.1%) on Oct 29, 2026
Insmed Appoints Two New Directors to Its Board
Oct 20, 2026
Closed $95.67 (+0.4%) on Oct 20, 2026
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
Oct 19, 2026
Closed $95.29 (-1.0%) on Oct 19, 2026
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
Oct 15, 2026
Closed $99.21 (+1.5%) on Oct 15, 2026
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
Oct 14, 2026
Closed $97.79 (+1.0%) on Oct 14, 2026
Insmed Announces CFO Transition
Oct 5, 2026
Closed $103.83 (-6.6%) on Oct 5, 2026
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Sep 21, 2026
Closed $121.00 (+0.8%) on Sep 21, 2026
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Sep 16, 2026
Closed $122.58 (+2.2%) on Sep 16, 2026
Insmed Incorporated on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 210 in all · newest Nov 4, 2026 · oldest 2019
- Calls
- 23 calls with a replay · 23 with a transcript · latest Oct 29, 2026
- Decks
- 50 decks · latest Oct 29, 2026
Where Insmed Incorporated is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:INSM · Home listing | NASDAQ | United States | USD |
| gettex:IM8N | gettex | Germany | EUR |
| Tradegate:IM8N | Tradegate | Germany | EUR |
| LSE:0JAV | LSE | United Kingdom | USD |
| LS Exchange:A1JJA3 | LS Exchange | Germany | EUR |
| BMV:INSM | BMV | Mexico | MXN |
| BOATS:INSM | BOATS | United States | USD |
| Lang & Schwarz:A1JJA3 · This page | Lang & Schwarz | Germany | EUR |
| Milan:1INSM | Milan | Italy | EUR |
| Stuttgart:IM8N | Stuttgart | Germany | EUR |
| BIVA:INSM | BIVA | Mexico | MXN |
| Frankfurt:IM8N | Frankfurt | Germany | EUR |
| BX Swiss:IM8N | BX Swiss | Switzerland | CHF |
| Hamburg:IM8N | Hamburg | Germany | EUR |
| Dusseldorf:IM8N | Dusseldorf | Germany | EUR |
| Hanover:IM8N | Hanover | Germany | EUR |
| Xetra:IM8N | Xetra | Germany | EUR |
Valuation
EV/sales 20.0× against a median of 8.1×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $30.41B USD
- P/E
- Loss
- EV/sales
- 20.0×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 42.7×
- Gross margin
- 84.4%
- Operating margin
- −37.1%
- Net margin
- −39.9%
- Debt to equity
- 0.8×
- Beta vs S&P 500
- 0.01
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Insmed Incorporated · NASDAQ:INSM | US$31.01B | US$30.41B | n/a | 20.0× | n/a | 42.7× | −39.9% | 0.8× | 0.01 |
| CSL Limited · ASX:CSL | US$62.67B | US$72.05B | n/a | 4.6× | 14.3× | 4.2× | −16.4% | 0.7× | n/a |
| Biogen Inc. · NASDAQ:BIIB | US$36.89B | US$42.88B | 106× | 4.2× | n/a | 1.9× | 3.4% | 0.4× | 0.34 |
| Genmab A/S · OMXCOP:GMAB | US$31.30B | US$34.64B | 42.9× | 8.1× | 24.4× | 4.9× | 17.0% | 0.8× | n/a |
| Roivant Sciences Ltd. · NASDAQ:ROIV | US$27.92B | US$23.82B | n/a | 580× | n/a | 7.0× | −838.2% | 0.0× | 1.00 |
| Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY | US$19.26B | US$15.68B | 7.3× | n/a | n/a | 5.3× | n/a | 0.0× | 0.58 |
| Ascendis Pharma A/S · NASDAQ:ASND | US$16.73B | US$16.15B | 17.1× | 12.2× | 61.1× | 10.0× | 73.5% | 0.3× | 0.49 |
| Exelixis, Inc. · NASDAQ:EXEL | US$15.77B | US$14.88B | 17.8× | 6.0× | n/a | 8.6× | 35.4% | 0.0× | 0.69 |
| Neurocrine Biosciences, Inc. · NASDAQ:NBIX | US$15.24B | US$14.50B | 21.7× | 3.9× | n/a | 3.9× | 19.0% | 0.0× | 0.79 |
| PharmaEssentia Corp. · TWSE:6446 | US$15.10B | US$14.39B | 65.3× | 22.9× | 56.4× | 13.5× | 36.8% | 0.0× | n/a |
| BridgeBio Pharma, Inc. · NASDAQ:BBIO | US$14.86B | US$15.95B | n/a | 16.9× | n/a | n/a | −59.8% | n/a | 0.89 |
| Median of the others | US$18.00B | US$16.05B | 21.7× | 8.1× | 40.4× | 5.3× | 17.0% | 0.0× | 0.69 |
Forecasts
18 strong buy · 5 buy · 1 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 194.18 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.67 · 17 analysts
- Revenue, year to Dec 2026
- 1.86B · 20 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| William H. Lewis | Chair and Chief Executive Officer |
| Roger Adsett | Chief Operating Officer |
| Michael Smith | Chief Legal Officer |
| Bryan Dunn | Vice President, Investor Relations |
| Claire Mulhearn | Vice President, Corporate Communications |
| Adele Deering | Senior Vice President, Portfolio Strategy & Operational Excellence |
| Samuele Butera | Senior Vice President, General Manager, Global Respiratory |
| Christie Camelio | Chief Compliance Officer |
| Eugene Sullivan | Chief Product Strategy Officer |
| Kevin Mange | Chief Development Officer |
| Martina Flammer | Chief Medical Officer |
| Nicole Schaeffer | Chief People Strategy Officer |
Board
| Director | Role |
|---|---|
| William H. Lewis | Chair and Chief Executive Officer |
| Carol A. Schafer | Director |
| Clarissa Desjardins | Director |
| David R. Brennan | Lead Independent Director |
| Elizabeth McKee Anderson | Director |
| Gianna De PalmaAssociate | Director |
| Leo Lee | Director |
| Melvin Sharoky | Director |
| Paul Hudson | Director |
| Utpal Koppikar | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Insmed (NASDAQ:INSM) Q3 2026 Earnings Call | Thu, Oct 29, 2026 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q1 2026 Earnings Call | Thu, May 07, 2026 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q4 2025 Earnings Call | Thu, Feb 19, 2026 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q3 2025 Earnings Call | Thu, Oct 30, 2025 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q4 2024 Earnings Call | Thu, Feb 20, 2025 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q3 2024 Earnings Call | Thu, Oct 31, 2024 · 8:00 AM ET | Replay |
| Insmed (NASDAQ:INSM) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:00 AM ET | Replay |
All 23 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · Before open | +15.1% |
| Q2 2026 | Aug 6, 2026 · Before open | +33.9% |
| Q1 2026 | May 7, 2026 · Before open | −23.4% |
| Q4 2025 | Feb 19, 2026 · Before open | +6.5% |
| Q3 2025 | Oct 30, 2025 · Before open | +16.3% |
| Q2 2025 | Aug 7, 2025 · Before open | −1.8% |
| Q1 2025 | May 7, 2025 · Before open | +0.6% |
| Q4 2024 | Feb 20, 2025 · Before open | −0.3% |
| Q3 2024 | Oct 31, 2024 · Before open | −4.3% |
| Q2 2024 | Aug 8, 2024 · Before open | +1.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +1.5% |
| Q4 2023 | Feb 22, 2024 · Before open | −3.9% |
| Q3 2023 | Oct 26, 2023 · Before open | +0.4% |
| Q2 2023 | Aug 3, 2023 · Before open | +1.8% |
| Q1 2023 | May 4, 2023 · Before open | −1.2% |
| Q4 2022 | Feb 23, 2023 · Before open | −2.5% |
| Q3 2022 | Oct 27, 2022 · Before open | −4.1% |
| Q2 2022 | Aug 4, 2022 · Before open | +15.2% |
| Q1 2022 | May 5, 2022 · Before open | +0.7% |
| Q4 2021 | Feb 17, 2022 · Before open | −2.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 27 slides | Oct 29, 2026 |
| Investor Presentation (October 2026) | Investor deck | 99 slides | October 2026 |
| Q2 2026 Earnings Presentation | Earnings | 27 slides | Aug 6, 2026 |
| Investor Presentation (August 2026) | Investor deck | 97 slides | August 2026 |
| Technical Presentation (July 2026) | Technical | 27 slides | Jul 16, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 29 slides | May 7, 2026 |
| Technical Presentation (March 2026) | Technical | 19 slides | Mar 23, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 24 slides | Feb 19, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 24 slides | Jan 9, 2026 |
| Fact Sheet (November 2025) | Fact sheet | 1 slide | November 2025 |
All 50 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$750M · US$96 a share · Goldman Sachs & Co. LLC +5 Dealers: Goldman Sachs & Co. LLC (lead), Leerink Partners (lead), BofA Securities (lead), Jefferies (lead), J.P. Morgan (lead), Stifel (co-lead) Use of proceeds: R&D and commercialization of brensocatib, ARIKAYCE commercialization and development, TPIP, INS1201 and pre-clinical research, and general corporate purposes | Jun 11, 2025 |
| Public offering of common stock Announced: US$650M · Goldman Sachs & Co. LLC +1 Dealers: Goldman Sachs & Co. LLC (co-lead), Leerink Partners (co-lead) | Jun 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 606.4M | 363.7M | 305.2M | 245.4M | 188.5M | 164.4M | 136.5M | 9.84M | 0 | 0 |
| Cost of revenue | 122.9M | 85.7M | 65.6M | 55.1M | 44.2M | 39.9M | 24.2M | 2.42M | 0 | 0 |
| Gross profit | 483.5M | 278.0M | 239.6M | 190.2M | 144.3M | 124.5M | 112.3M | 7.41M | 0 | 0 |
| Research and development | 771.1M | 598.4M | 571.0M | 397.5M | 272.7M | 181.2M | 131.7M | 145.3M | 109.7M | 122.7M |
| Selling, general and administrative | 701.2M | 461.1M | 344.5M | 265.8M | ||||||
| Operating income | -1.25B | -878.3M | -709.6M | -457.3M | -375.1M | -265.2M | -235.2M | -307.3M | -188.9M | -173.4M |
| Depreciation and amortization | 10.4M | 5.96M | 5.50M | 5.30M | 9.10M | 9.10M | 5.20M | 3.60M | 2.90M | 2.40M |
| EBITDA | -1.24B | -872.3M | -704.1M | -452.0M | -366.0M | -256.1M | -230.0M | -303.7M | -186.0M | -171.0M |
| Interest expense | 83.8M | 84.9M | 81.7M | 26.4M | 40.5M | 29.6M | 27.7M | 25.5M | 5.92M | 3.50M |
| Income before tax | -1.27B | -910.1M | -747.0M | -480.2M | -436.4M | -292.7M | -253.6M | -324.1M | -192.9M | -176.2M |
| Income tax | 5.03M | 3.71M | 2.56M | 1.38M | -1.76M | 1.40M | 777.0K | 201.0K | -272.0K | 98.0K |
| Net income | -1.28B | -913.8M | -749.6M | -481.5M | -434.7M | -294.1M | -254.3M | -324.3M | -192.6M | -176.3M |
| Earnings per share, basic | -6.42 | -5.57 | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 |
| Earnings per share, diluted | -6.42 | -5.57 | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 510.4M | 555.0M | 482.4M | 1.07B | 716.8M | 532.8M | 487.4M | 495.1M | 381.2M | 162.6M |
| Short-term investments | 919.6M | 878.8M | 298.1M | 74.2M | 0 | |||||
| Receivables | 140.9M | 52.0M | 41.2M | 29.7M | 24.4M | 16.6M | 19.2M | 5.51M | 0 | |
| Inventory | 132.1M | 98.6M | 83.2M | 69.9M | 67.0M | 49.6M | 28.3M | 7.03M | 0 | |
| Current assets | 1.79B | 1.62B | 929.1M | 1.27B | 837.0M | 622.9M | 555.2M | 518.9M | 389.4M | 168.4M |
| Property, plant and equipment | 102.9M | 80.1M | 65.4M | 56.5M | 53.0M | 54.0M | 60.2M | 22.6M | 12.4M | 10.0M |
| Goodwill | 136.1M | 136.1M | 136.1M | 136.1M | 136.1M | 0 | ||||
| Total assets | 2.26B | 2.03B | 1.33B | 1.66B | 1.24B | 796.2M | 742.3M | 604.6M | 462.0M | 238.0M |
| Accounts payable | 79.9M | 73.0M | 65.4M | 50.5M | 35.8M | 42.9M | 13.2M | 17.7M | 14.7M | 10.4M |
| Current liabilities | 468.9M | 297.5M | 225.6M | 190.2M | 135.2M | 118.8M | 85.2M | 79.7M | 44.7M | 28.0M |
| Long-term debt | 541.0M | 1.10B | 1.16B | 1.13B | 566.6M | 356.3M | 335.9M | 316.6M | 55.6M | 54.8M |
| Total debt | 546.8M | 1.12B | 1.18B | 1.15B | 800.0M | 450.0M | 450.0M | 450.0M | 55.0M | 55.0M |
| Total liabilities | 1.53B | 1.74B | 1.66B | 1.57B | 833.0M | 520.3M | 480.6M | 396.3M | 101.0M | 83.5M |
| Shareholders' equity | 739.0M | 285.4M | -331.9M | 88.0M | 410.5M | 275.9M | 261.7M | 208.3M | 361.1M | 154.5M |
| Shares outstanding | 214.3M | 179.4M | 148.0M | 135.7M | 118.7M | 102.8M | 89.7M | 77.3M | 76.6M | 62.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -935.0M | -683.9M | -536.2M | -400.4M | -363.3M | -219.3M | -250.6M | -258.0M | -159.6M | -146.7M |
| Capital spending | -32.6M | -21.9M | -13.3M | -9.88M | -7.29M | -6.24M | -42.3M | -13.1M | -3.00M | -4.20M |
| Free cash flow | -967.6M | -705.8M | -549.5M | -410.3M | -370.6M | -225.6M | -292.9M | -271.1M | -162.6M | -150.9M |
| Cash from investing | -64.6M | -583.2M | -223.6M | -34.6M | -64.3M | -6.82M | -42.3M | -14.8M | -3.00M | -4.20M |
| Cash from financing | 954.1M | 1.34B | 168.4M | 793.3M | 612.5M | 271.0M | 285.3M | 386.7M | 381.1M | 30.7M |
| Change in cash | -44.6M | 72.7M | -591.7M | 357.3M | 184.0M | 45.3M | -7.64M | 113.9M | 218.6M | -120.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Nov 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 20, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 20, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 5, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 6, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 23, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 22, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| S-3ASR · Registration statement | May 15, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 8-K · Current report | May 15, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 7, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Apr 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 1, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 30, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 19, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 19, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 12, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 18, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 4, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
This page holds 200 of 1,013 filings. Open Filings
Cap table
Built by 6ix from Insmed Incorporated’s releases · as of Oct 23, 2026
- Common shares
- 219,380,309
- Fully diluted
- 219,380,309
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 219,380,309 | Oct 23, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 23, 2026 | 219,380,309 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Myrtle S Potter Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Since at least Jun 13, 2024); Guardant Health, Inc. (Director · Since at least Oct 15, 2021); Immunovant, Inc. (Director · Dec 18, 2019 – Dec 18, 2019 · Past); Arbutus Biopharma Corporation (Director · Oct 18, 2018 – Aug 17, 2019 · Past); Sio Gene Therapies Inc (Director · Sep 26, 2018 – Apr 15, 2019 · Past); Urovant Sciences Ltd (Director · Sep 26, 2018 – Mar 29, 2021 · Past); Myovant Sciences Ltd (Director · Sep 20, 2018 – Mar 10, 2023 · Past); Axsome Therapeutics, Inc. (Director · Jun 16, 2017 – Jun 7, 2019 · Past); Everyday Health Inc (Director · Mar 27, 2014 – Dec 3, 2016 · Past); Rite Aid Corporation (Director · Nov 29, 2013 – Oct 3, 2017 · Past) | Director · Dec 11, 2014 – May 15, 2018 · Past |
| Christine Pellizzari Other companies: NeuroSense Therapeutics Ltd. (Board Member · Since at least Mar 18, 2026); Tempest Therapeutics, Inc. (Director · Since at least Jul 1, 2021); Imunon, Inc. (Director · Since at least Jun 8, 2021); LifeSci Acquisition II Corp (Chief Legal and HR Officer · Oct 6, 2021 – Mar 12, 2024 · Past); Aegerion Pharmaceuticals Inc (EVP, Gen. Counsel & Secretary · Oct 21, 2010 – Oct 21, 2010 · Past); Dendrite International Inc (Sr VP, General Counsel & Secty · May 1, 2006 – May 9, 2007 · Past) | Chief Legal Officer · Jul 29, 2013 – May 15, 2021 · Past |
| Carol A. Schafer Other companies: Immunome, Inc. (Director · Since at least Jan 2, 2024); Kura Oncology, Inc. (Director · Since at least Jun 3, 2021); Repare Therapeutics Inc (Director · Since at least May 13, 2021); Five Prime Therapeutics Inc (Director · Apr 16, 2021 – Apr 16, 2021 · Past); Aceragen Inc. (Director · Oct 1, 2020 – Jun 23, 2022 · Past) | Director · Since at least May 12, 2021 |
| David McGirr Other companies: X4 Pharmaceuticals, Inc. (Director · Since at least Nov 15, 2017); Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past); Cubist Pharmaceuticals Inc (SVP & Chief Financial Officer · Mar 31, 2010 – Feb 15, 2013 · Past) | Director · Since at least Oct 30, 2013 |
| Richard S Kollender Other companies: Rapid Micro Biosystems, Inc. (Director · Since at least Jul 14, 2021); Strongbridge Biopharma plc (President and CFO · Jan 1, 2018 – Oct 5, 2021 · Past); Celator Pharmaceuticals Inc (Director · Jan 14, 2013 – Jun 20, 2016 · Past); NuPathe Inc. (Director · Aug 5, 2010 – Feb 21, 2014 · Past) | Director · Jan 12, 2011 – Oct 31, 2013 · Past |
| Stephen C. Glover Other companies: Oncolytics Biotech Inc. (Director · Since at least Jun 1, 2026); ZyVersa Therapeutics, Inc. (Co-founder, Chairman, CEO, and President · Since at least Dec 12, 2022); PDS Biotechnology Corporation (Director · Since at least Apr 2, 2019); Ambrx Biopharma Inc. (Director · May 18, 2023 – Mar 7, 2024 · Past) | President Follow-on Biologics · Jun 22, 2007 – Mar 31, 2009 · Past |
| Alfred Altomari Other companies: Recro Pharma Inc (Director · Mar 12, 2014 – Dec 5, 2019 · Past); Auxilium Pharmaceuticals Inc (Director · Jun 6, 2006 – Jun 16, 2011 · Past); Barrier Therapeutics Inc (Chief Executive Officer, Director · Mar 31, 2006 – Aug 5, 2008 · Past) | Director · Aug 2, 2012 – May 13, 2024 · Past |
| Donald J Hayden Jr Other companies: Theseus Pharmaceuticals Inc (Director · May 17, 2022 – Feb 14, 2024 · Past); Amicus Therapeutics Inc (Director · Jan 2, 2018 – Jun 7, 2018 · Past); Regenxbio Inc. (Director · Oct 11, 2017 – May 29, 2020 · Past) | Director · Nov 14, 2017 – Apr 9, 2019 · Past |
| Paul Streck Other companies: PepGen Inc. (Executive Vice President, Head of Research & Development · Since at least Aug 19, 2024); Albireo Pharma Inc (Chief Medical Officer · Dec 19, 2022 – Mar 2, 2023 · Past); Alder BioPharmaceuticals Inc (Chief Medical Officer · Jan 21, 2019 – Oct 22, 2019 · Past) | Chief Medical Officer · Jun 5, 2017 – Aug 8, 2018 · Past |
| Sara Bonstein Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Xilio Therapeutics, Inc. (Chair of the Board · Since at least Jun 15, 2022); Scpharmaceuticals Inc (Director · Since at least Jun 14, 2022) | Chief Financial Officer · Since at least May 11, 2022 |
All 46 people
| Person | Seat |
|---|---|
| Utpal Koppikar Other companies: C4 Therapeutics, Inc. (Director · Since at least Mar 16, 2022); Flexion Therapeutics Inc (Director · Jul 9, 2021 – Nov 19, 2021 · Past); Atara Biotherapeutics, Inc. (Chief Financial Officer · Jun 7, 2018 – Mar 2, 2023 · Past) | Director · Since at least Oct 19, 2026 |
| William H. Lewis Other companies: NewAmsterdam Pharma Company N.V. (Director · Since at least Jan 4, 2024); uniQure N.V. (Director · Jan 1, 2017 – Jan 27, 2017 · Past); Aegerion Pharmaceuticals Inc (President, PFO and Treasurer · Oct 21, 2010 – Oct 27, 2010 · Past) | Chair and Chief Executive Officer · Since at least Sep 10, 2012 |
| Elizabeth McKee Anderson Other companies: Revolution Medicines, Inc. (Director · Since at least Feb 12, 2020); BioMarin Pharmaceutical Inc. (Director · Since at least Jul 8, 2019) | Director · Since at least Nov 6, 2018 |
| Melvin Sharoky Other companies: Par Pharmaceutical Companies Inc (Director · Mar 8, 2007 – Sep 28, 2012 · Past); Andrx Corp (Director · Feb 28, 2006 – Nov 3, 2006 · Past) | Director · Since at least May 10, 2006 |
| Renu Gupta Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Nov 24, 2014 – May 25, 2017 · Past); Agenus Inc. (Sr. VP Development · Feb 24, 2006 – Jul 20, 2006 · Past) | Executive Vice President & CMO · Dec 1, 2010 – Jan 31, 2014 · Past |
| Roger Adsett Other companies: Definium Therapeutics, Inc. (Director · Since at least Jan 29, 2026); Landos Biopharma Inc (Director · Mar 8, 2022 – May 23, 2024 · Past) | Chief Operating Officer · Since at least Sep 27, 2016 |
| Clarissa Desjardins Other companies: Xenon Pharmaceuticals Inc. (Director · Jan 13, 2020 – Jun 1, 2020 · Past) | Director · Since at least Nov 12, 2019 |
| Dennis M. Lanfear Other companies: Coherus Oncology, Inc. (President & Chief Executive Officer · Since at least Nov 6, 2014) | Director · Dec 6, 2007 – Jun 9, 2010 · Past |
| John Goll Other companies: Immunocore Holdings plc (SVP, FINANCE & CAO · Since at least Jan 2, 2024) | Chief Accounting Officer · Jun 3, 2019 – Jan 3, 2020 · Past |
| Orlov S Nicole Schaeffer Other companies: Amicus Therapeutics Inc (SVP, HR & Leadership Devt · Feb 3, 2009 – Feb 15, 2012 · Past) | Chief People Strategy Officer · Since at least Jun 2, 2014 |
| Randall W Whitcomb Other companies: Tempest Therapeutics, Inc. (Director · Dec 7, 2018 – Jun 20, 2019 · Past) | Director · Jan 10, 2014 – Mar 10, 2015 · Past |
| Adele Deering | Senior Vice President, Portfolio Strategy & Operational Excellence · Since at least Nov 4, 2026 |
| Andrea Holtzman Drucker | SVP, Gen. Counsel & Corp Sec. · Jul 18, 2011 – Jun 3, 2013 · Past |
| Bryan Dunn | Vice President, Investor Relations · Since at least Aug 6, 2026 |
| Christie Camelio | Chief Compliance Officer · Since at least Nov 5, 2026 |
| Claire Mulhearn | Vice President, Corporate Communications · Since at least Aug 6, 2026 |
| David R. Brennan | Lead Independent Director · Since at least May 11, 2022 |
| Doug Farrar | Vice President, ITP · Nov 1, 2006 – Mar 31, 2009 · Past |
| Eugene Sullivan | Chief Product Strategy Officer · Since at least Mar 23, 2015 |
| Geoffrey Allan | President, CEO and Chairman, Director · Jun 21, 2007 – Mar 31, 2009 · Past |
| Gianna De PalmaAssociate | Director · Since at least Oct 20, 2026 |
| Glen L Kelley | VP, REGULATORY AFFAIRS · Mar 31, 2009 – Mar 31, 2009 · Past |
| John Drayton Wise | Chief Commercial Officer · May 23, 2022 – Feb 5, 2025 · Past |
| John Soriano | Chief Compliance Officer · Jan 3, 2021 – Sep 7, 2021 · Past |
| Kenneth G Condon | Director · May 9, 2007 – Jun 9, 2010 · Past |
| Kevin Mange | Chief Development Officer · Since at least Nov 5, 2026 |
| Kevin P Tully | Executive VP & CFO · Feb 20, 2006 – Dec 21, 2011 · Past |
| Leo Lee | Director · Since at least May 15, 2018 |
| Martina Flammer | Chief Medical Officer · Since at least Dec 16, 2019 |
| Michael Smith | Chief Legal Officer · Since at least Jul 8, 2021 |
| Nicholas Lee Gurreri | Senior VP, Commercial Ops · Jan 31, 2011 – Jan 31, 2011 · Past |
| Nicole Schaeffer | Chief People Strategy Officer · Since at least Sep 16, 2026 |
| Paul Hudson | Director · Since at least Oct 19, 2026 |
| Peggy Berry | Vice President, Regulatory · Jun 2, 2014 – Feb 26, 2015 · Past |
| Samuele Butera | Senior Vice President, General Manager, Global Respiratory · Since at least Jun 23, 2026 |
| Timothy Whitten | President & CEO, Director · Dec 1, 2010 – Jun 1, 2012 · Past |
Log in to ask 6ix AI your own questions about Insmed Incorporated.